Use and Safety of Remdesivir in Kidney Transplant Recipients With COVID-19

Introduction:Remdesivir has demonstrated antiviral activity against coronavirus, shortening the time torecovery in adults hospitalized with moderate/severe COVID-19. Severe adverse events such as acutekidney injury have been reported. Scant data are available on the use and safety of remdesivir in k...

Descripción completa

Detalles Bibliográficos
Autores: Buxeda, Anna, Arias Cabrales, Carlos, Pérez Sáez, María José, Cacho, Judit, Cabello Pelegrin, Sheila, Melilli, Edoardo, Aladrén, María José, Galeano, Cristina, Lorenzo, Inmaculada, Mazuecos, Auxiliadora, Saura, Isabel María, Franco, Antonio, Ruiz Fuentes, María del Carmen, Sánchez Cámara, Luis Alberto, Siverio, Orlando, Martín Conde, María Luisa, González García, Elena, López, Verónica, Martin Moreno, Paloma Leticia, Moina, Iñigo, Moral Berrio, Esperanza, Moreso, Francesc, Portolés, José María, Santana Estupiñán, Raquel, Zárraga, Sofía, Canal, Cristina, Sánchez Álvarez, Emilio, Pascual, Julio, Crespo, Marta
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:10459.1/72336
Acceso en línea:https://doi.org/10.1016/j.ekir.2021.06.023
http://hdl.handle.net/10459.1/72336
Access Level:acceso abierto
Palabra clave:Acute kidney
Injury
Immunosuppression
Kidney transplantation
Remdesivir
SARS-CoV2
Descripción
Sumario:Introduction:Remdesivir has demonstrated antiviral activity against coronavirus, shortening the time torecovery in adults hospitalized with moderate/severe COVID-19. Severe adverse events such as acutekidney injury have been reported. Scant data are available on the use and safety of remdesivir in kidneytransplant recipients.Methods:We present a multicenter cohort study of 51 kidney transplant recipients with COVID-19 treatedwith remdesivir. Outcomes and safety were assessed.Results:Mean age at diagnosis was 60 years, with a median time since kidney transplant of 4.5years. Mean time since admission to remdesivir was 2 days. Twenty-eight patients (54.9%) requiredmechanical ventilation (19 noninvasive). Mortality was 18.9% and markedly higher if aged$65 years(45% vs. 3.2% in younger patients). Acute kidneyinjury was present in 27.7% of patients, but wasdiagnosed in 50% before treatment. No patients required remdesivir discontinuation because ofadverse events. We did notfind significant hepatoxicity or systemicsymptoms resulting from thedrug. Conclusion:In our cohort of kidney transplant recipients, remdesivir was well tolerated and safe in renaland hepatic toxicity, but randomized trials are needed to assess its efficacy.

Similares en LA Referencia